HOME >> MEDICINE >> NEWS
Updated data compares DOXIL (R)/CAELYX (TM) (doxorubicin HCl liposome injection) to Topotecan

Bridgewater, NJ, November 4, 2003 Researchers have presented updated data comparing DOXIL/CAELYX (doxorubicin HCl liposome injection) to topotecan HCl in patients with recurrent ovarian cancer. These data, from a randomized, controlled, multi-center, open-label, Phase III clinical study, were presented during a poster session at the 12th meeting of the Federation of European Cancer Societies (ECCO 12) in Copenhagen, Denmark.1

The National Cancer Institute estimates that in 2003, 25,000 American women will be diagnosed with ovarian cancer, and 14,000 women will die from it.2 This analysis compared DOXIL and topotecan another common treatment for recurrent ovarian cancer in epithelial ovarian cancer patients whose disease recurred after or did not respond to first-line, platinum-based chemotherapy. The primary objective of this long-term follow up analysis was to measure the overall survival and progression-free survival of these patients.

Researchers reported the median overall survival was three weeks longer for patients treated with DOXIL compared to those treated with topotecan (63 and 60 weeks, respectively, HR 0.82 [95 percent CI = 0.68 to 1.00]; p = 0.05). In addition, the overall progression-free survival was 16.1 weeks for DOXIL compared to 17.0 weeks topotecan (HR 0.88 [95 percent CI = 0.73 to 1.06]; p = 0.171).

Among platinum-sensitive patients (those who had a PFS interval of greater than six months after first-line, platinum-based chemotherapy), the median survival of patients receiving DOXIL was 112 weeks versus 77 weeks for patients receiving topotecan (HR 0.63 [95 percent CI = 0.47 to 0.85]; p = 0.002). DOXIL patients also saw a significant advantage in median PFS versus those receiving topotecan (28.9 and 23.1 weeks, respectively, HR = 0.76 [95 percent CI = 0.58 to 1.00]; p = 0.046).

In the subset of patients with platinum-refractory disease (those whose disease progressed during in
'"/>


4-Nov-2003


Page: 1 2 3

Related medicine news :

1. Updated adjuvant data presented at SABCS show 30 percent reduction in recurrence
2. Updated press release to October 2004 Cochrane Review
3. Newly Updated HIV Treatment Guidelines For Adults And Adolescents Available On The World Wide Web
4. Updated Results On Heart Assist Device Presented At International Transplant Meeting
5. Multi-center trial compares three medications in patients with heart failure
6. Study compares overnight dialysis to treatment in centers
7. Study compares clinical diagnoses and autopsy diagnoses in ICU deaths
8. New Commonwealth Fund analysis compares candidtes health care reform proposals
9. Study compares three weekly regimens of chemotherapy for lung cancer
10. Lung cancer screening trial compares CT and standard x-ray
11. Study compares efficacy and adherence to triple nucleoside therapy Ziagen + Combivir with protease inhibitor plus Combivir regimens in therapy-nave

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... ... December 07, 2016 , ... ... bioelectronic medicine device WellnessPro Plus for consumers and healthcare professionals to manage ... platform by expanding the treatment modalities available in a single device. The ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Fred Rides a Train” allows readers to ... , “Fred Rides a Train” is the creation of published author, Janet Morrison, ... teen years in Michigan. The "Fred, the Dog" series is her first attempt at ...
(Date:12/7/2016)... ... December 07, 2016 , ... "Hacking into my medical ... described him as 'a genius.'" Thus begins "Margaret in Berlin," Book Twelve in the ... by Wyston Books, Inc. These novels narrate the lives of a poor ...
(Date:12/6/2016)... ... , ... According to a November 1 article published on Bustle, ... not drinking enough water, which can cause bad breath (known medically as halitosis). Dr. ... hygiene not only helps reduce the possibility of bad breath, but it can provide ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... the Maine Women’s Magazine inaugural Maine Women’s Expo. Hundreds of women gathered to ... amazing local resource. The expo’s beneficiary this year was Crossroads, a fully-accredited ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... LONDON , Dec. 6, 2016 /PRNewswire/ ... Review, H2 2016 Summary Global ... pipeline guide Homozygous Familial Hypercholesterolemia (HoFH) – ... of the Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic ... is a genetic disorder which is caused ...
(Date:12/6/2016)... , Dec. 6, 2016   AlloSource , ... cellular, bone, skin and soft-tissue allografts for use ... Business Process Manager, for being named to the ... National Quality Award by the Commerce Department,s National ... organization,s commitment to process excellence. The Baldrige Award ...
(Date:12/6/2016)... , Dec. 6, 2016 Two new ... personnel in a simulated mass casualty event Tuesday at ... . The technology debuted before an audience including ... and representatives from Homeland Security, Federal Law Enforcement Agencies, ... Project, known as HiRO (Health Integrated Rescue Operations), was ...
Breaking Medicine Technology:
Cached News: